FORM PTO-14	149			SERIAL NO.		10/533,73	34	
	ON DISCLOSURE ST		FILING DATE			May 4, 2005		
THE CALL PROPERTY OF THE PROPE				APPLICANT			Ertl	
				GROUP		1648		
				EXAMINER		Kinsey		
					DOCKET NO	<del></del>	[[C	
		U.S. P	ATENT DO		DOCKET NO.	.   PG50231	USW	
Examiner Initials	Patent	Issue Date		ame	Class	Subclass	Filing Date If Appropria	
Initials	Number							
		FOREIG	N PATENT I	DOCUMENTS	5			
	Document Number	Publication Date		untry	Class	Subclass	Translation Yes   No	
	99/016884	08 April 1999	WO					
	02/099101	12 Dec 2002	WO					
	02/0220080	21 Mar 2002	WO					
	04/041851	21 May 2004	WO					
	1015596	30 Aug 2006	EP					
	OTHER DOCU	MENTS (Includi	ng Author, T	itle. Journal-F	Date. Page Nun	nher. Etc.)		
		MENTS (Includi					d individuals	
	Asjo et al., Phase	e 1 trial of a therap	eutic HIV typ	oe 1 vaccine, V	acc-4x, in HIV	type 1-infecte		
	Asjo et al., Phase with or without a	e 1 trial of a therap antiretroviral thera	peutic HIV typ py, AIDS Res	oe 1 vaccine, V s Hum Retrovii	acc-4x, in HIV ruses 18(18):13	type 1-infecte 57-1365 (Dec	2002)	
	Asjo et al., Phase with or without a Azad et al., Larg	e 1 trial of a therapantiretroviral thera e-scale production	peutic HIV typ py, AIDS Res	oe 1 vaccine, V s Hum Retrovii	acc-4x, in HIV ruses 18(18):13	type 1-infecte 57-1365 (Dec	2002)	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199	e 1 trial of a therap antiretroviral thera re-scale production (4)	peutic HIV typ pp, AIDS Res n and characte	oe 1 vaccine, V s Hum Retroving rization of reco	acc-4x, in HIV ruses 18(18):13 ombinant HIV-	type 1-infecte 57-1365 (Dec 1 Nef, J. Gener	2002) ral Virology,	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199 Berzofsky, Prog	e 1 trial of a therap antiretroviral thera e-scale production 4) ress toward an arti	peutic HIV typ py, AIDS Resonand characte vicial vaccine	be 1 vaccine, V s Hum Retroving rization of reco	face-4x, in HIV ruses 18(18):13 ombinant HIV- tification of hel	type 1-infecte 57-1365 (Dec 1 Nef, J. Gener per and cytoto	2002) ral Virology,	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199 Berzofsky, Progepitopes and me	e 1 trial of a therap antiretroviral thera ge-scale production (4) ress toward an artithods of immuniza	peutic HIV typ ppy, AIDS Reson and characte vicial vaccine ation, Biotechn	be 1 vaccine, V is Hum Retroving rization of reconstruction of reconstruction of reconstruction. Therefore, 2(1-2)	facc-4x, in HIV ruses 18(18):13 ombinant HIV- tification of hel 2): 123-135 (19	type 1-infecte 57-1365 (Dec 1 Nef, J. Gener per and cytoto 91)	2002) ral Virology, xic T-cell	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin	e 1 trial of a therap antiretroviral thera ge-scale production (4) ress toward an artithods of immunizational antigens for H	peutic HIV typepy, AIDS Reson and character vicial vaccine ation, Biotechnic IV vaccines by	be 1 vaccine, Ves Hum Retroving rization of record for HIV: identification of the control of the	Tacc-4x, in HIV ruses 18(18):13 ombinant HIV- tification of hel 2): 123-135 (19 - T response, pr	type 1-infecte 57-1365 (Dec 1 Nef, J. Gener per and cytoto 91)	2002) ral Virology, xic T-cell	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA	e 1 trial of a therap antiretroviral thera ge-scale production (4) ress toward an artithods of immunizational antigens for Hand Cell Biology 21(	peutic HIV typepy, AIDS Research and character avicial vaccine ation, Biotechn (IV vaccines by):665-670 (S	be 1 vaccine, Ves Hum Retroving rization of record for HIV: identical three rich assed on CD8 + ept. 2002)	Tacc-4x, in HIV ruses 18(18):13 ombinant HIV- tification of hel 2): 123-135 (19 - T response, pr	type 1-infecte 57-1365 (Dec 1 Nef, J. Gener per and cytoto 91) rotein length, a	2002) ral Virology, xic T-cell and sequence	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., Th	e 1 trial of a therap antiretroviral therap e-scale production (4) ress toward an artithods of immunization mal antigens for Hand Cell Biology 21( erapeutic vaccinat	peutic HIV typ ppy, AIDS Res and characte vicial vaccine ation, Biotechn IIV vaccines b 9):665-670 (S ion with MVA	se 1 vaccine, V s Hum Retroving rization of reconstruction of reconstruction of reconstruction. Ther. 2(1-2) assed on CD8 + ept. 2002) A-HIV-1 nef el	ruses 18(18):13 ombinant HIV- tification of hel 2): 123-135 (19 - T response, pricits Nef-specifi	type 1-infecte 57-1365 (Dec 1 Nef, J. Gener per and cytoto 91) rotein length, a	2002) ral Virology, xic T-cell and sequence	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral an artithods of immunizamal antigens for Ha Cell Biology 21(erapeutic vaccinatal infected individual	peutic HIV typ ppy, AIDS Res and characte evicial vaccine ation, Biotechn IIV vaccines b 9):665-670 (S ion with MVA luals, Vaccine	se 1 vaccine, Vac Hum Retroving rization of reconstruction of reconstruction of reconstruction of the reconstr	racc-4x, in HIV ruses 18(18):13 combinant HIV- tification of hel 2): 123-135 (19 - T response, pr icits Nef-specif Dec 2003)	type 1-infecte 57-1365 (Dec 1 Nef, J. Gener per and cytoto 91) totein length, a ic T-helper ce	2002) ral Virology, xic T-cell and sequence	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Mult	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral thods of immunizational antigens for Hacell Biology 21(erapeutic vaccinatal infected individiple effects of cod	peutic HIV typ. ppy, AIDS Responsed and character vicial vaccines by 1:665-670 (Sion with MV Aluals, Vaccine on usage optim	se 1 vaccine, Vac Hum Retroving rization of record	facc-4x, in HIV ruses 18(18):13 ombinant HIV- tification of hel 2): 123-135 (19 - T response, pr icits Nef-specif Dec 2003) pression and in	type 1-infected 57-1365 (Dec 1 Nef, J. General eytoto 91) rotein length, a lic T-helper cemunogenicity	2002) ral Virology, xic T-cell and sequence Il responses in of DNA	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral thods of immunizational antigens for Hacell Biology 21(erapeutic vaccinated infected individuals effects of codues encoding the hammunical trial	peutic HIV typ. ppy, AIDS Responsed and character vicial vaccines by 1:665-670 (Sion with MV Aluals, Vaccine on usage optim	se 1 vaccine, Vac Hum Retroving rization of record	facc-4x, in HIV ruses 18(18):13 ombinant HIV- tification of hel 2): 123-135 (19 - T response, pr icits Nef-specif Dec 2003) pression and in	type 1-infected 57-1365 (Dec 1 Nef, J. General eytoto 91) rotein length, a lic T-helper cemunogenicity	2002) ral Virology, xic T-cell and sequence Il responses in of DNA	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral thodous of immunizational antigens for Hacell Biology 21(erapeutic vaccinated infected individuals effects of codues encoding the hacell (2001)	peutic HIV typ. ppy, AIDS Responsed and character ation, Biotechn ation, Biote	se 1 vaccine, Vac Hum Retroving rization of reconstruction of reconstruction of reconstruction of the reconstr	facc-4x, in HIV ruses 18(18):13 ombinant HIV- tification of hel 2): 123-135 (19 - T response, pr icits Nef-specif Dec 2003) pression and im- us type 1 Gag p	type 1-infected 57-1365 (Dec 1 Nef, J. General Per and cytoto 91) totein length, a cic T-helper communogenicity rotein, J. Viro	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., 9	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral thorapantiretroviral and antigens for Hacell Biology 21(erapeutic vaccinated infected individuals effects of codues encoding the hacell (2001)	peutic HIV typ. ppy, AIDS Responsed and character ation, Biotechn ation with MVA at a second at a seco	se 1 vaccine, Vac Hum Retroving rization of reconstruction of reconstruction of reconstruction of the reconstr	facc-4x, in HIV ruses 18(18):13 ombinant HIV- tification of hel 2): 123-135 (19 - T response, pricits Nef-specif Dec 2003) pression and im- us type 1 Gag p	type 1-infected 57-1365 (Dec 1 Nef, J. General Per and cytoto 91) totein length, a cic T-helper communogenicity rotein, J. Viro	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV	e 1 trial of a therap antiretroviral thera ge-scale production (4) ress toward an arti- thods of immuniza- mal antigens for H a Cell Biology 21( erapeutic vaccinate- 1 infected individ- iple effects of cod- ges encoding the har- 001 (2001) Comprehensive de V-1 regulatory pro-	peutic HIV typepy, AIDS Research and character avicial vaccine ation, Biotechn are the period of the	to be 1 vaccine, Very Hum Retroving rization of record for HIV: identification of the control of	racc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 - T response, pricits Nef-specif Dec 2003) pression and impus type 1 Gag promunogenic pro 1092 (1993)	type 1-infected 57-1365 (Dec 1 Nef, J. General Per and cytoto 91) rotein length, a fic T-helper centurogenicity protein, J. Viropperties of pep	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien	e 1 trial of a therap antiretroviral therap de-scale production (4) ress toward an arti- thods of immuniza- mal antigens for Handler Cell Biology 21( erapeutic vaccinated infected individ- iple effects of cod- dues encoding the handler (2001) Comprehensive deviced in the control of the cont	peutic HIV typepy, AIDS Research and character avicial vaccine atton, Biotechn articles by 1:665-670 (Strong with MVA duals, Vaccine on usage optimuman immuno delineation of attein, Vaccine pecific immuno opeptide vaccine and the strong was a strong with the strong was a strong with the strong was a str	to be 1 vaccine, Very Hum Retroving rization of record for HIV: identification of the control of	racc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 - T response, pricits Nef-specif Dec 2003) pression and impus type 1 Gag promunogenic pro 1992 (1993) duced in human	type 1-infected 57-1365 (Dec 17-1365) (Dec 1	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11	e 1 trial of a therap antiretroviral therap de-scale production (4) ress toward an arti- thods of immuniza- mal antigens for Hand Cell Biology 21( erapeutic vaccinata- 1 infected individ- iple effects of cod- dues encoding the hand (2001) Comprehensive dev- V-1 regulatory pro- et al., Long term sp cy virus type 1 lip 220-11231 (Oct. 2	peutic HIV typepy, AIDS Research and character avicial vaccine attion, Biotechn IIV vaccines by 1:665-670 (Stion with MVA duals, Vaccine on usage optimuman immuno belineation of attein, Vaccine pecific immunopeptide vaccine 2003)	se 1 vaccine, Vac Hum Retroving rization of reconstruction of reco	ruses 18(18):13 combinant HIV- cuses 18(18):13 combinant HIV- cuses 18(18):13 combinant HIV- cuses 18(18):13 combinant HIV- cuses 18(18):13 cuses 18(18):13 cuses 18(18):13 cuses 19 cu	type 1-infected 57-1365 (Dec 17-1365) (Dec 1	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optivariability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et al., 100 Gahery-Segard et al., 10	e 1 trial of a therap antiretroviral therap ee-scale production (4) ress toward an arti- thods of immuniza- mal antigens for Hand Cell Biology 21( erapeutic vaccinata- 1 infected individ- iple effects of cod- ues encoding the hand Comprehensive dev V-1 regulatory pro- et al., Long term sp cy virus type 1 lip 220-11231 (Oct. 2 et al., Multiepitopi	peutic HIV typepy, AIDS Research and character avicial vaccine attion, Biotechn IIV vaccines by 1:665-670 (Sion with MVA duals, Vaccine on usage optimuman immuno belineation of attein, Vaccine pecific immunopeptide vaccine 1:003) c B- and T-ce	be 1 vaccine, Vac Hum Retroving rization of reconstruction of reco	racc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 - T response, pricits Nef-specific Dec 2003) pression and impus type 1 Gag promunogenic pro 192 (1993) duced in human relation of CD8+there with the control of the con	type 1-infected 57-1365 (Dec 17-1365) (Dec 1	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et immunodeficien	e 1 trial of a therapentiretroviral therapentiretroviral therapentiretroviral therapentiretroviral therapentiretroviral therapentiretroviral an artithods of immunizamal antigens for Handler Cell Biology 21(erapeutic vaccinatal infected individual infected infected infected individual infected inf	peutic HIV typepy, AIDS Reson and character avicial vaccine attion, Biotechn IIV vaccines by 9):665-670 (Sion with MVA luals, Vaccine on usage optimuman immuno petine tien, Vaccine pecific immunopeptide vaccine and T-ce opeptide vaccine opeptide opeptide opeptide vaccine opeptide opeptid	se 1 vaccine, Vac Hum Retroving rization of reconstruction of reco	racc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 Tesponse, pricits Nef-specific Dec 2003) pression and impus type 1 Gag promunogenic pro 192 (1993) duced in human 2 action of CD8+tipe 194-1703	type 1-infected 57-1365 (Dec 17-1365) (Dec 1	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et immunodeficien Hinkula et al., R	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral analysis and antigens for Handler Cell Biology 21(erapeutic vaccinatal infected individual infected indi	peutic HIV typepy, AIDS Reson and characted avicial vaccines attion, Biotechn attion, Waccines on usage optimuman immunos attein, Vaccine attein, Vaccin	se 1 vaccine, Vac Hum Retroving rization of reconstruction of reco	racc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 Tesponse, pricits Nef-specific Dec 2003) pression and impus type 1 Gag promunogenic pro 192 (1993) duced in human 2 action of CD8+tipe 194-1703	type 1-infected 57-1365 (Dec 17-1365) (Dec 1	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et immunodeficien Hinkula et al., Rigenes, J. Virologe	e 1 trial of a therapentiretroviral therapentiretroviral therapentiretroviral therapentiretroviral therapentiretroviral therapentiretroviral an artithods of immunizamal antigens for Handler Cell Biology 21(erapeutic vaccinatal infected individual infected infected infected individual infected inf	peutic HIV typepy, AIDS Research and character and character artion, Biotechnot artion, Biotechnot artion, Biotechnot artion, Biotechnot articles are are articles are articles are article	se 1 vaccine, Vac Hum Retroving rization of reconstruction of reco	facc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 Tesponse, pricits Nef-specific Dec 2003) pression and in us type 1 Gag promunogenic pro 192 (1993) duced in human 2 tation of CD8+tuced in human 4(4):1694-1703 by immunization	type 1-infected 57-1365 (Dec 17-1365) (Dec 1	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived s recognized, J	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et immunodeficien Hinkula et al., Rigenes, J. Virolog Johnson and Wa	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral an artited and antigens for Handler and Antigens for Handle	peutic HIV typepy, AIDS Research and character and character artion, Biotechnot artion, Biotechnot artion, Biotechnot artion, Biotechnot articles are are articles are articles are article	se 1 vaccine, Vac Hum Retroving rization of reconstruction of responses in reconstruction of rec	racc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 Tresponse, pricits Nef-specific Dec 2003) pression and in us type 1 Gag promunogenic pro 192 (1993) duced in human ration of CD8+thuced in human 4(4):1694-1703 by immunization of deficiency valued in human the specific property of the specifi	type 1-infected 57-1365 (Dec 17-1365) (Dec 1	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived s recognized, J	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Prog epitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et immunodeficien Hinkula et al., R genes, J. Virolog Johnson and Wastructural protein	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral an artist thods of immunization and antigens for Hard Cell Biology 21(erapeutic vaccinatal infected individual infected infected in the infected individual infected infected infected in the infected individual infected infecte	peutic HIV typepy, AIDS Research and character and character are included in an and character are included in a second in the se	the I vaccine, Vaccine, Vaccine, Vaccine, Vaccine, Vaccine, Vaccine, Vaccine, Vaccine, III.  The second of the sec	facc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 - T response, pricits Nef-specific Dec 2003) pression and impus type 1 Gag promunogenic pro 192 (1993) duced in human 194 at 194 at 195 at 1	type 1-infected 57-1365 (Dec 17-1365 (Dec 17-1365) (Dec 17	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived s recognized, J	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Prog epitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et immunodeficien Hinkula et al., R genes, J. Virolog Johnson and Wastructural protein Kmieciak et al.,	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral and antigens for Harden and American antigens for Harden antigens for	peutic HIV typepy, AIDS Research and character and character are periodically vaccines by 1:665-670 (Sion with MVA duals, Vaccine on usage optimuman immuno periodical vaccine pecific immunopeptide vaccine pecific immunopeptide vaccine periodical vaccine period	the 1 vaccine, Vaccin	racc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of held 2): 123-135 (19-17) response, produced in human ration of CD8+1 duced in human rational ration of CD8+1 duced in human rational ration	type 1-infected 57-1365 (Dec 1 Nef, J. General Per and cytoto 91) rotein length, a fic T-helper centrologenicity rotein, J. Virologenicity operties of pepus by a human T cell epitopes as by a human (Feb. 2000) ion with HIV-rirus infection:	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived s recognized, J I regulatory responses to deficiency viru	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et immunodeficien Hinkula et al., Rigenes, J. Virolog Johnson and Wastructural protein Kmieciak et al., type 1 Gag and I	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral an artist thods of immunization and antigens for Hard Cell Biology 21(erapeutic vaccinatal infected individual infected infected in the infected individual infected infected infected in the infected individual infected infecte	peutic HIV typepy, AIDS Research and character and character arion, Biotechn ation, Waccines on usage optimuman immunor ation, Vaccine pecific immunopeptide vaccine and T-ceropeptide vaccine ation and T-ceropeptide vaccine ation at the period of the period at the period	be 1 vaccine, Vaccine	racc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of held 2): 123-135 (19-17) response, produced in human ration of CD8+1 duced in human rational ration of CD8+1 duced in human rational ration	type 1-infected 57-1365 (Dec 1 Nef, J. General Per and cytoto 91) rotein length, a fic T-helper centrologenicity rotein, J. Virologenicity operties of pepus by a human T cell epitopes as by a human (Feb. 2000) ion with HIV-rirus infection:	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived s recognized, J. I regulatory responses to deficiency viru	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard et immunodeficien Virol. 77(20):11 Gahery-Segard et immunodeficien Hinkula et al., Regenes, J. Virolog Johnson and Wastructural protein Kmieciak et al., type 1 Gag and I antigens, J Human Regenes, J. Human R	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral thods of immunization and antigens for Harden and Archive antigens for Harden and Archive antigens for Harden antigens for H	peutic HIV typepy, AIDS Research and character and character are periodically vaccines by 1:665-670 (Strong with MVA duals, Vaccines on usage optimuman immuno attein, Vaccine pecific immunopeptide vaccines on usage optimuman immuno attein, Vaccine pecific immunopeptide vaccines and T-ceropeptide vaccines opeptide vac	be 1 vaccine, Vaccine	facc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19-T response, pricits Nef-specific Dec 2003) pression and impusity per 1 Gag promunogenic pro 1092 (1993) duced in human relation of CD8+duced in human relation relatio	type 1-infected 57-1365 (Dec 17-1365 (Dec 17	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived s recognized, J I regulatory responses to deficiency viru	
	Asjo et al., Phase with or without a Azad et al., Larg 75:651-655 (199) Berzofsky, Progepitopes and me Betts et al., Optin variability, DNA Cosma et al., The chronically HIV Deml et al, Multicandidate vaccin 75(22);10991-11 Estaquier et al., from the nef HIV Gahery-Segard esimmunodeficien Virol. 77(20):11 Gahery-Segard esimmunodeficien Hinkula et al., Regenes, J. Virolog Johnson and Wastructural proteir Kmieciak et al., type 1 Gag and I antigens, J Huma Letvin et al., Pro	e 1 trial of a therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral therapantiretroviral thods of immunization and antigens for Harden and antigens of the color	peutic HIV typepy, AIDS Research and character and character arion, Biotechn ation, Waccines on usage optimuman immunor ation, Vaccine pecific immunopeptide vaccine pecific immunopeptide vaccine and T-ceopeptide vaccine ation, Vaccine pecific immunopeptide vaccine and T-ceopeptide vaccine ation at the pecific immunopeptide vaccine at the pecific immunopeptide vaccine at the pecific immunopeptide vaccine at the pecific immunolellular and hunon protein expectation at the pecific immunolellular and hunon pecific immunolell	the I vaccine, Vaccine, Vaccine, Vaccine, Vaccine, Vaccine, Vaccine, Vaccine, Vaccine, III.  Trization of record of the III.  Ther. 2(1-2) assed on CD8 + ept. 2002)  A-HIV-1 nef el 22(1), 21-29 (mization on expediciency viruntigenic and in 11(11):1083-10 the responses incine; characterization, J. Virol. 7-phitopes induced in human immun. 189:35-63 (19) moral immune pressing highly highly in HIV-1 Vaccine.	facc-4x, in HIV ruses 18(18):13 ombinant HIV-tification of hel 2): 123-135 (19 Tesponse, pricits Nef-specific Dec 2003) pression and impusity per 1 Gag promunogenic pro 1092 (1993) duced in human relation of CD8+duced in human relation of CD8+duced in human relation of CD8+duced in human responses to her immunogenic me, Science 280 me, Science 280 me, Science 280 me, Science 280 metallic statements of the	type 1-infected 57-1365 (Dec 17-1365 (Dec 17	2002) ral Virology, xic T-cell and sequence Il responses in of DNA logy tides derived s recognized, J. I regulatory responses to deficiency viruand Pol p51	

Page 1 of 2

			1480 1 012			
		Robert Guroff, HIV Regulatory and accessory proteins, new targets for vaccine development, DNA and Cell Biology, 21(9): 597-598 (Sept 2002)				
		Zur Megede et al., Increased expression and immunogenicity of sequence modified HIV-1 gag gene, J. Virology 74:2628 (2000)				
EXAMINER		DATE CONSIDERED				
		if citation considered, whether or not citation is in conformance with formance and not considered. Include copy of this form with next com				